Enantioselective Total Synthesis of (‐)‐Finerenone using Asymmetric Transfer Hydrogenation
2020
(-)-Finerenone is a nonsteroidal mineralocorticoid receptor antagonist currently in phase III clinical trials for the treatment of chronic kidney disease in type 2 diabetes. It contains an unusual dihydronaphthyridine core. Herein, we report a 6-step synthesis of (-)-Finerenone which features an enantioselective partial transfer hydrogenation of a naphthyridine using a chiral phosphoric acid catalyst with a Hantzsch ester. The process is complicated by the fact that the naphthyridine exists as a mixture of two atropisomers which react at different rates and different selectivities. The intrinsic kinetic resolution was converted into a kinetic dynamic resolution at elevated temperature which enabled us to obtain (-)-Finerenone in both high yield and high enantioselectivity. DFT calculations have revealed the origin of selectivity.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
33
References
1
Citations
NaN
KQI